Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

velop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

* the adequacy of the Company's patents and proprietary rights;

* the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

* the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

* the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Brian Korb

The Trout Group

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 15, 2014 Organovo Holdings, Inc. (NYSE ... on delivering breakthrough 3D bioprinting technology,  today celebrated ... of its exVive3D TM Human Liver Tissue.  ... full commercial release on November 18, has been ... several awards for innovation. Most recently, ...
(Date:12/15/2014)... , Dec. 15, 2014  Origin Agritech Limited (NASDAQ GS: ... technology-focused supplier of crop seeds in China ... its fiscal year 2014 ended September 30, 2014, before the ... Company will host a teleconference on January 8, 2015, at ... time to discuss the results. To participate in the ...
(Date:12/13/2014)... CanDiag, Inc., a University of North Carolina ... name to OncoTab, Inc. , “The new name ... today,” said CEO and Chief Science Officer, Dr. Pinku ... cancer diagnostics to include imaging and therapies, and our ... Founded in 2011 by Dr. Mukherjee, an Irwin Belk ...
(Date:12/13/2014)... Maryland (PRWEB) December 12, 2014 Clarassance, ... today announced its new name: Therabron Therapeutics , ... therapy and bronchioles (a type of structure in the ... the company’s mission to develop novel protein therapeutics for ... of directors decided to change the name to mark ...
Breaking Biology Technology:Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc. 2Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... , , , , ... Specific technique considerations , , , ... First, verify that both ,of your DNA constructs work in your cell line. Also, determine ... 3 l FuGENE 6 Reagent) that ,provides good expression levels. Then, perform the transfection, ensuring ...
... , , , ... , , , , ... that can be transfected using ,currently available transfection reagents, there are ... of cell. In certain cell ,types, such as HeLa, K-562, and ...
... , , , , ... , plasmid purification system that can be completed ... traditional plasmid purification chemistries, SprintPrep isolates , plasmid ... time of a sequencing pipeline by as much as a ...
Cached Biology Technology:Uses and Applications of FuGENE 6 Transfection Reagent 2Uses and Applications of X-tremeGENE Q2 Transfection Reagent 2SPRINTPREP SINGLE STEP PLASMID PURIFICATION 2SPRINTPREP SINGLE STEP PLASMID PURIFICATION 3
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... in the world. This is having a major impact, but ... cities on rural areas. One of the most important ecological ... from the University of Twente has reviewed the problem in ... . She says "A hundred years ago 95% of the ...
... 1 January 2009 the Deutsche Forschungsgemeinschaft (DFG, German Research ... will be initially funded for the next four years ... other things, the new Collaborative Research Centres will study ... scarring of the liver and kidneys, and the human ...
... related topics raises unique challenges not often encountered ... article, a team of researchers use specific examples ... systematic reviews relevant to nutrition and discuss the ... reviews, also referred to as evidence-based reviews, provide ...
Cached Biology News:From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 2From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 4From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 5From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 6From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 7Experts discuss applying systematic review to the field of nutrition 2
This monoclonal antibody recognizes the light chain of human Factor XII and at 100 nM inhibits 50% of Factor XII activity. It may be used in ELISA to detect human Factor XII and in coagulation assay...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Biology Products: